A new interview highlights the efforts of the Food and Drug Administration’s Office of Minority Health. In it, the director of this branch of the FDA explains how her office attempts to analyze how medical items could have different impacts on certain minority sections of the population. She points to warfarin as one drug that has different effects depending on the ethnicity of the individual receiving the treatment. She also says that clinical trials can be improved by getting women and minorities more involved, as doing otherwise means that risks to certain people might go undetected until the repercussions are made known outside of a controlled setting.
Click here to learn more about the office.